GET DAILY SIGNALSMannatech (MTEX): A Closer Look at the Glyconutrient Wellness Company
Key Takeaways
- MTEX is the ticker for Mannatech, Incorporated, a global health and wellness company focused on nutritional supplements, skincare, and weight-management products.
- Founded in 1993 and headquartered in Flower Mound, Texas, the company markets products through a network of independent associates and e-commerce channels.
- Mannatech's flagship product line is built around its proprietary Ambrotose glyconutrient technology.
- The company's financial profile shows a small-cap business with a multinational footprint spanning the Americas, Asia-Pacific, and EMEA regions.
- Its business model depends on a direct-selling salesforce, which carries both competitive and regulatory considerations.
Company Overview
Mannatech, Incorporated develops, markets, and sells nutritional supplements, skincare and anti-aging products, and weight-management items. Listed on Nasdaq under the ticker MTEX, the firm appeals to consumers interested in support for overall health, immune function, weight management, and skin vitality. From what I see, investors track this small-cap name in the fragmented nutritional supplement space because of its proprietary glyconutrient technology and network-marketing approach.
Business and Product Details
Mannatech was incorporated in November 1993 by Marlin Ray Robbins and Samuel L. Caster and is based in Flower Mound, Texas. With roughly 170 employees, it runs sales operations across more than two dozen markets in North America, Asia-Pacific, Europe, and Africa. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The product portfolio breaks down into several categories:
- Integrative Health — daily nutritional supplements and wellness products, including the flagship Ambrotose and Advanced Ambrotose lines, Manapol Powder, and MannaBears.
- Targeted Health — items focused on specific areas, such as CardioBALANCE, GI-ProBalance, and ImmunoSTART.
- Weight and Fitness — offerings such as OsoLean, SPORT, and the TruHealth Fat Loss System.
- Skin Care — a K-Beauty-inspired line, including Luminovation, Emprizone, and FIRM with Ambrotose.
- Essentials — value-oriented dietary supplements with simpler ingredient profiles.
At the core of the company’s identity is its glyconutrient technology, based on plant-derived carbohydrates known as glycans. Mannatech positions these proprietary blends as differentiators in a market often seen as commodity-driven. A meaningful portion of revenue comes from its Ambrotose and TruHealth product families.
The business model centers on direct selling. Independent associates buy products at wholesale and either use them personally or resell them, earning commissions and incentives tied to sales volume. The company also runs a non-direct-selling operation in mainland China and supports ordering through e-commerce. Primary revenue comes from product sales to associates and preferred customers, plus associate fees. In recent years, the Asia-Pacific region has represented the largest share of revenue, followed by the Americas and EMEA.
What Draws Investors to MTEX
Mannatech stands out as a differentiated, proprietary-technology story in the wellness sector. Its glyconutrient-focused platform provides a distinct position compared with many generic vitamin and supplement makers. The diversified geographic presence can help reduce reliance on any single market while tapping into growing consumer demand for health and wellness products in areas such as Asia.
The direct-selling model is capital-light and tends to support healthy cash-flow characteristics and solid return on invested capital, since the company avoids maintaining a large store network. Its emphasis on science-backed formulations and quality assurance, including third-party manufacturing and certifications, supports brand positioning. For investors interested in small-cap consumer-health companies with a global direct-sales footprint, Mannatech offers a niche but clearly defined opportunity.
Key Risks to Consider
Investing in Mannatech involves several important considerations. The company operates in an intensely competitive and highly fragmented nutritional supplement industry, facing large consumer-products and pharmaceutical firms as well as many smaller direct-selling competitors.
Reliance on network marketing brings regulatory scrutiny. Multi-level marketing structures fall under oversight by agencies such as the U.S. Federal Trade Commission and equivalent bodies abroad, and adverse rulings or rule changes could affect the compensation model or require costly adjustments. The business also depends on continued recruitment and retention of independent associates; high turnover or negative publicity around the direct-selling model could pressure revenue.
As a seller of dietary supplements, Mannatech faces product-liability, product-claim, and compliance risks across many jurisdictions. Its financial profile as a small-cap company with modest revenue and profitability levels makes it potentially more sensitive to macroeconomic conditions, foreign-exchange movements, and shifts in consumer spending than larger, more diversified peers.
Using AI Tools in My Research Process
When I want to explore broader market context around names like MTEX, I turn to Tickeron’s AI Screener. This platform helps filter thousands of securities by technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and custom criteria. It lets me narrow ideas efficiently to match specific investment strategies and adds useful perspective to company-level analysis.
Conclusion
Mannatech is a compact yet globally distributed wellness company whose identity rests on proprietary glyconutrient technology and a direct-selling distribution network. Its differentiated product platform and broad international footprint set it apart within the nutritional supplement industry, while its reliance on independent associates and a competitive regulatory environment remain central to understanding the business. For investors, Mannatech offers a focused way to evaluate the intersection of consumer health trends and the network-marketing model, though its small size and industry dynamics warrant careful consideration.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MTEX in upward trend: price rose above 50-day moving average on October 19, 2026
MTEX moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 50 of 55 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MTEX as a result. In 91 of 117 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Following a +11.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTEX advanced for three days, in 137 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 106 of 122 cases where MTEX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for MTEX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In 49 of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
MTEX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTEX's P/B Ratio (-3.149) is slightly lower than the industry average of (3.045). P/E Ratio (-2.074) is within average values for comparable stocks, (55.291). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (0.741). MTEX's Dividend Yield (0.099) is considerably higher than the industry average of (0.015). P/S Ratio (0.139) is also within normal values, averaging (0.357).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. MTEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTEX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of nutritional supplements, topical products, and weight-management products
Industry FoodDistributors
Advertisement